Our findings demonstrate that CUDC-907 successfully resensitizes tumors to progestin therapy by upregulating PR expression, downregulating the obesity-related factor IGF-1, and inhibiting the PI3K/Akt/mTOR signaling pathway. Here, IGF1 is linked to obesity due to melanocortin 4 receptor deficiency.